Literature DB >> 7831536

Assessing prognosis and predicting patient outcomes in community-acquired pneumonia.

K Gilbert1, M J Fine.   

Abstract

Community-acquired pneumonia is a common medical illness, with clinical outcomes ranging from mild illness with rapid and complete recovery to a fulminant clinical course with morbid complications followed by death. A systematic review of the literature on pneumonia prognosis has identified a variety of demographic factors, symptoms and physical examination findings, comorbid illnesses, laboratory abnormalities, and etiologic agents that are independently associated with short-term mortality in patients with this illness. By combining these prognostic factors, investigators have developed a variety of indices to predict short-term mortality. Although these predictive instruments vary with respect to the patient populations studied, number of predictor variables included, statistical methods used, and overall clinical performance, these models can assist physicians in assessing patient prognosis and in making important management decisions such as the initial site of care (ie, home v hospital). Assessment of patient prognosis has also been used by clinicians and health services researchers who use the hospital severity of illness-adjusted mortality rate as a measure of the quality of medical care provided. Because the majority of patients with this illness survive, future assessments or predictions of prognosis in patients with community-acquired pneumonia should also evaluate a spectrum of other important health outcome measures including the occurrence of morbid complications, symptom resolution, quality of life, return to work and usual activities, and patient satisfaction with care.

Entities:  

Mesh:

Year:  1994        PMID: 7831536

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  16 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Regulatory disincentives for developing antibiotics for common indications.

Authors:  Guy W Amsden
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 3.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 4.  Changing needs of community-acquired pneumonia.

Authors:  Julio Alberto Ramirez; Antonio R Anzueto
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

5.  Validation of the pneumonia severity index. Importance of study-specific recalibration.

Authors:  W D Flanders; G Tucker; A Krishnadasan; D Martin; E Honig; W M McClellan
Journal:  J Gen Intern Med       Date:  1999-06       Impact factor: 5.128

6.  Association of hypoglycemia with mortality for subjects hospitalized with pneumonia.

Authors:  Eric M Mortensen; Sean Garcia; Luci Leykum; Brandy Nakashima; Marcos I Restrepo; Antonio Anzueto
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

Review 7.  Targeted antioxidants as therapeutics for treatment of pneumonia in the elderly.

Authors:  Stefi F Lee; Rebecca Harris; Heather W Stout-Delgado
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

8.  Treatment of Community-Acquired Pneumonia Requiring Admission to a Hospital Ward.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

9.  The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

Authors:  Eric M Mortensen; Marcos I Restrepo; Antonio Anzueto; Jacqueline Pugh
Journal:  BMC Pulm Med       Date:  2005-09-13       Impact factor: 3.317

10.  Impact of prior outpatient antibiotic use on mortality for community acquired pneumonia: a retrospective cohort study.

Authors:  Eric M Mortensen; Marcos I Restrepo; Jacqueline A Pugh; Antonio Anzueto
Journal:  BMC Res Notes       Date:  2008-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.